Photo by nci from unsplash
Abstract Purpose We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. Methods irAEs were defined using medical and pharmacy claims for patients enrolled in a… Click to show full abstract
Abstract Purpose We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. Methods irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018. Results Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs. Conclusion These data underscore the needs for tailored irAE diagnostic and management pathways.
Journal Title: Cancer Investigation
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!